| Similar Articles |
|---|
 |
Chemistry World
July 29, 2015
Phillip Broadwith |
Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments.   |
Chemistry World
February 18, 2010
Matt Wilkinson |
Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
Pharmaceutical Executive
November 1, 2008
Jim Wahl |
The Mess in MS A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri. |
The Motley Fool
May 26, 2004
Charly Travers |
Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon. |
The Motley Fool
March 16, 2007
Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool
May 2, 2007
Brian Lawler |
Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note. |
The Motley Fool
July 26, 2006
Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. |
The Motley Fool
June 30, 2005
Brian Gorman |
Teva's Non-Generic Side The drug company is working hard to cement its position in the market for multiple sclerosis meds. Investors, take note. |
The Motley Fool
November 26, 2007
Brian Lawler |
Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan. |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
August 19, 2010
Brian Orelli |
High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS. |
The Motley Fool
July 24, 2007
Brian Lawler |
Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line. |
The Motley Fool
February 18, 2004
Jeff Hwang |
Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule. |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
Chemistry World
October 1, 2008
Victoria Gill |
GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy. |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool
November 24, 2004
Charly Travers |
A Blockbuster Drug Gains Approval Biogen IDEC and Elan announced that Tysabri had been approved by the FDA for the treatment of muliple sclerosis (MS). Tysabri has long been regarded as a drug that will generate a whopping level of sales. |
The Motley Fool
October 24, 2007
Brian Lawler |
Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results. |
The Motley Fool
September 21, 2006
Brian Lawler |
Another Partner for Biogen The pharmaceutical enlists help to thwart a troublesome illness. After the market closed yesterday, Biogen added another collaboration agreement with Alnylam Pharmaceuticals to its long list of partners. Investors, take note. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
April 25, 2008
Brian Lawler |
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. |
The Motley Fool
June 23, 2011
Brian Orelli |
One Less Oral MS Drug to Worry About But competition is still tough. |
The Motley Fool
January 7, 2009
Brian Orelli |
A Free Call Option on a Drug Orphan-drug specialist BioMarin announces that it has licensed Riquent, La Jolla Pharmaceutical's phase 3 lupus nephritis treatment. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
September 14, 2006
Brian Lawler |
Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note. |
BusinessWeek
March 14, 2005
Arnst & Barrett |
Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments |
The Motley Fool
December 4, 2009
Brian Orelli |
Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet. |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved. |
Managed Care
January 2008 |
Too Few Programs to Manage MS? Disease management programs for patients with multiple sclerosis improve outcomes and adherence, reduce disability, and contains cost, but there are not enough of them in existence. |
The Motley Fool
September 30, 2009
Brian Orelli |
Less Is More for Novartis That makes it simple enough. |
The Motley Fool
March 10, 2010
Brian Orelli |
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. |
The Motley Fool
October 31, 2011
Brian Orelli |
When You've Got It, You've Got It Biogen keeps its good-news streak going. |
BusinessWeek
March 21, 2005
Catherine Arnst |
On The Hot Seat At Biogen How Biogen CEO Jim Mullen managed a drug crisis after alarming news broke that the multiple sclerosis drug Tysabri may cause a deadly brain infection. |
Chemistry World
April 27, 2010
Anna Lewcock |
Massive payout for 'toxic sofa' victims A UK high court judge has awarded 20 million in payouts to 1650 people who sustained chemical burns from dimethyl fumarate in sofas manufactured in China. |
The Motley Fool
October 27, 2011
Brian Orelli |
DEFINE First, CONFIRM Second, See Shares Rise 60% Third Biogen CONFIRMs it has a new blockbuster drug and shares jump. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
April 11, 2008
Brian Orelli |
Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug. |
The Motley Fool
April 14, 2011
Frank Vinluan |
Biogen Idec Inks Biotech Blood Products Research Deal With Amunix The exclusive, worldwide research collaboration agreement calls for both companies to jointly conduct preclinical research. |
The Motley Fool
March 11, 2005
Karl Thiel |
Better Times at Biogen IDEC Is now the time to buy this pharmaceutical? |
